Comment on "Under the Hood: Evidence-Based Review of Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies" [0.03%]
关于“深入探讨：异体嵌合抗原受体T细胞治疗血液系统恶性肿瘤的证据为基础的分析”的评论
S Dhanya Dedeepya,Vaishali Goel,Nivedita Nikhil Desai
S Dhanya Dedeepya
Response to "Comment on Under the Hood: Evidence-Based Review of Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies [0.03%]
对“关于基于证据的同种异体嵌合抗原受体T细胞治疗血液系统恶性肿瘤的评论”的回应
Asfand Yar Cheema,Hossam M Ali,Mishaal Munir et al.
Asfand Yar Cheema et al.
Late toxicity of allogeneic stem cell transplantation for Non-Hodgkin lymphoma patients. SBST based analysis 1997-2021 and review of literature [0.03%]
非霍奇金淋巴瘤患者异基因干细胞移植后长期毒性：基于SBRT的分析（1997-2021）及文献回顾
A von Werdt,A Künzi,A Haynes et al.
A von Werdt et al.
Background: allogeneic stem cell transplantation (allo-HSCT) represents so far the only potentially curable treatment according to a longest follow in a setting of relapse/refractory NHL (rrNHL). Given the improvement of ...
Belumosudil for Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis [0.03%]
贝卢莫司滴针对慢性移植物抗宿主病的疗效：系统评价和 meta 分析
Kristin Rathje,Nico Gagelmann,Silke Heidenreich et al.
Kristin Rathje et al.
Background: Chronic graft-versus-host disease (cGvHD) is a debilitating complication following allogeneic hematopoietic stem cell transplantation, often refractory to standard therapies. Belumosudil, a selective ROCK2 inh...
Acute Toxicities and Early Outcomes of Tandem Autologous Stem Cell Transplantation in Pediatric High-Risk Neuroblastoma: A Multicenter Study [0.03%]
儿童高危神经母细胞瘤自体造血干细胞移植急性毒性反应和近期结果的多中心研究
Zahra Hudda,Aaron Webster,Eric Anderson et al.
Zahra Hudda et al.
Background: High-dose chemotherapy with tandem autologous stem cell transplantation (ASCT) is a standard approach for pediatric high-risk neuroblastoma (HR-NB). However, data on acute regimen-related toxicities are limite...
Elevation of White Blood Cell Count after G-CSF-Combined Conditioning Predicts Relapse and Disease-Free Survival Following Single-Unit Cord Blood Transplantation for Myeloid Malignancies: WBC Elevation with G-CSF Conditioning Predicts Relapse after CBT [0.03%]
G-CSF预处理后白细胞计数升高可预测单份脐带血移植治疗髓系肿瘤的复发和无病生存：G-CSF预处理后WBC升高可预测CBT后的复发
Shohei Andoh,Seiko Kato,Jun Ooi et al.
Shohei Andoh et al.
Background: Granulocyte colony-stimulating factor (G-CSF) enhances the cytotoxicity of cytarabine (Ara-C) against myeloid leukemia cells, and G-CSF-combined conditioning regimens have been adopted in single-unit cord bloo...
In reply to: Pretransplant Conditioning for Haematopoietic Cell Transplants: The Past is Prologue [0.03%]
答：造血干细胞移植的预处理：过去即序章
Michael Williams,Sanja Zepcan,Justin Graff et al.
Michael Williams et al.
EASIX Does Not Add Prognostic Value Beyond Lactate Dehydrogenase and ECOG Performance Status in CAR T-Cell Therapy: A GETH-TC Study [0.03%]
EASIX不能在CAR-T细胞治疗中乳酸脱氢酶和ECOG体能状态的基础上增加预后价值：一项GETH-TC研究的结果
Marta Peña,Diego Fernando Martinez,Lucía López-Corral et al.
Marta Peña et al.
The Endothelial Activation and Stress Index (EASIX) has been proposed as a predictor of endothelial complications such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients undergo...
CRISPR Knockdown of CHIP Genes in Macrophages Drives Increased Production of Inflammatory Cytokines in CAR-T Cell Therapy [0.03%]
通过CRISPR干扰小胶质细胞中的CHIP基因可增强CAR-T细胞治疗中炎症因子的产生
Chunyan Zhang,Scott R Goldsmith,Myo Htut et al.
Chunyan Zhang et al.
Clonal hematopoiesis of indeterminate potential (CHIP) is characterized by somatic mutations in leukemogenic genes (e.g., DNMT3A, TET2, and ASXL1) in hematopoietic stem cells and is linked to age-related clonal expansion and inflammation. W...
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting [0.03%]
来自临床试验和真实世界数据的利斯卡巴奇马莱祖克治疗后2周以上的CRS或ICANS罕见事件：来自临床试验和现实世界的资料
Bradley D Hunter,Matthew Lunning,Mazyar Shadman et al.
Bradley D Hunter et al.
Improved understanding of the timing of cytokine release syndrome (CRS) and immune effector cell-mediated neurotoxicity syndrome (ICANS)/neurological events (NE) after chimeric antigen receptor (CAR) T-cell therapy infusion can inform patie...